Patents by Inventor Vijay G. Sankaran

Vijay G. Sankaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY
    Publication number: 20220265863
    Abstract: Described herein are methods and compositions related to GATA-1 gene therapy for the treatment of Diamond-Blackfan anemia.
    Type: Application
    Filed: June 8, 2020
    Publication date: August 25, 2022
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Vijay G. SANKARAN, Richard A. VOIT, Leif S. LUDWIG
  • LINEAGE TRACING USING MITOCHONDRIAL GENOME MUTATIONS AND SINGLE CELL GENOMICS
    Publication number: 20210246503
    Abstract: Embodiments disclosed herein provide methods of using somatic mutations in mitochondrial genomes to retrospectively infer cell lineages in native contexts and to serve as genetic barcodes to measure clonal dynamics in complex cellular populations. Further, somatic mutations in mitochondrial DNA (mtDNA) are tracked by single cell genomic approaches for simultaneous analysis of single cell lineage and state. Applicants further show that mitochondrial mutations can be readily detected with contemporary single cell transcriptomic and epigenomic technologies to concomitantly capture gene expression profiles and chromatin accessibility, respectively.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 12, 2021
    Inventors: Leif S. Ludwig, Caleb A. Lareau, Jacob C. Ulirsch, Aviv Regev, Vijay G. Sankaran, Jason Buenrostro, Christoph Muus
  • Modulation of BCL11A for treatment of hemoglobinopathies
    Patent number: 10570392
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 25, 2020
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190169615
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 6, 2019
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. ORKIN, Vijay G. SANKARAN
  • Modulation of BCL11A for treatment of hemoglobinopathies
    Patent number: 10266826
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 23, 2019
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180179527
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Application
    Filed: February 5, 2018
    Publication date: June 28, 2018
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. ORKIN, Vijay G. SANKARAN
  • Modulation of BCL11A for treatment of hemoglobinopathies
    Patent number: 9885041
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: February 6, 2018
    Assignees: The Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • MODULATION OF SH2B3 TO IMPROVE RED BLOOD CELL PRODUCTION FROM STEM CELLS AND/OR PROGENITOR CELLS
    Publication number: 20170355958
    Abstract: Disclosed herein are methods for producing red blood cells (RBCs) from a population of stem cells and/or progenitor cells. In at least one of the stem cells or progenitor cells, SH2B3 protein activity is decreased, SH2B3 mRNA level is decreased, and/or SH2B3 protein level is decreased. The methods provided herein permit the production of RBCs with increased quantity and/or quality as compared to a method using the same population of stem cells and/or progenitor cells without SH2B3 inhibition or disruption. Also provided herein are methods of use of the RBCs produced using the methods described herein.
    Type: Application
    Filed: November 24, 2015
    Publication date: December 14, 2017
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Vijay G. SANKARAN
  • MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20170152513
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Application
    Filed: January 4, 2016
    Publication date: June 1, 2017
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • Modulation of BCL11A for treatment of hemoglobinopathies
    Patent number: 9228185
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: January 5, 2016
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20130129629
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Application
    Filed: January 17, 2013
    Publication date: May 23, 2013
    Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • Modulation of BCL11A for treatment of hemoglobinopathies
    Patent number: 8383604
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 26, 2013
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20110182867
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Application
    Filed: September 14, 2009
    Publication date: July 28, 2011
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Stuart H. Orkin, Vijay G. Sankaran